However, among clinical trials targeting glioblastoma, the only HDAC inhibitor that has progressed to a phase III trial is valproic acid (NCT03243461), and their high toxicity and low selectivity are considered to be major reasons for the limited success of other compounds [14]. Here, HDAC9 is linked to glioblastoma.